These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 36053612)

  • 21. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
    Nachman S; Alvero C; Acosta EP; Teppler H; Homony B; Graham B; Fenton T; Xu X; Rizk ML; Spector SA; Frenkel LM; Worrell C; Handelsman E; Wiznia A
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):e76-83. PubMed ID: 26582887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enablers of adherence to clinic appointments for children attending an antiretroviral clinic in Northern Nigeria: Perspectives of caregivers and care providers.
    Musa S; Umar LW; Abdullahi FL; Taegtemeyer M; Abdullahi SM; Olorukooba AA; Alfa AM; Usman NH
    J Trop Pediatr; 2019 Jun; 65(3):273-279. PubMed ID: 30085151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
    Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
    HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
    [No Abstract]   [Full Text] [Related]  

  • 25. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
    Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA
    PLoS One; 2015; 10(2):e0118228. PubMed ID: 25723472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health care workers' perspectives about disclosure to HIV-infected children; cross-sectional survey of health facilities in Gauteng and Mpumalanga provinces, South Africa.
    Madiba S; Mokgatle M
    PeerJ; 2015; 3():e893. PubMed ID: 25893147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study.
    Pavone P; Giustini N; Fimiani C; Paoletti F; Falciano M; Salotti A; Di Sora F; Al Moghazi S; Mezzaroma I; Vullo V; d'Ettorre G
    Curr HIV Res; 2017 Nov; 15(5):355-360. PubMed ID: 28969567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canadian tuberculosis health care workers' perspectives on education and counselling for patients and family members who are born outside of Canada.
    Bedingfield N; Lashewicz B; Fisher D; King-Shier K
    Glob Public Health; 2023 Jan; 18(1):2174265. PubMed ID: 36789497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort.
    Santinelli L; Ceccarelli G; Borrazzo C; Celani L; Pavone P; Innocenti GP; Spagnolello O; Fimiani C; Ceci F; Di Sora F; Mezzaroma I; Mastroianni CM; d'Ettorre G
    Expert Rev Anti Infect Ther; 2020 May; 18(5):485-492. PubMed ID: 32096433
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of breastfeeding care and education given to mothers with low-birthweight babies by healthcare workers at a hospital in urban Tanzania: a qualitative study.
    Tada K; Shimpuku Y; Sunguya B; Horiuchi S
    Int Breastfeed J; 2020 May; 15(1):36. PubMed ID: 32375834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing the Emergency Triage, Assessment and Treatment plus admission care (ETAT+) clinical practice guidelines to improve quality of hospital care in Rwandan district hospitals: healthcare workers' perspectives on relevance and challenges.
    Hategeka C; Mwai L; Tuyisenge L
    BMC Health Serv Res; 2017 Apr; 17(1):256. PubMed ID: 28388951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Option B+ Program for the Prevention of Vertical Transmission of HIV: A Case Study in Johannesburg, South Africa.
    Bisnauth MA; Coovadia A; Mbuagbaw L; Wilson MG; Birch S
    Front Public Health; 2020; 8():533534. PubMed ID: 33194942
    [No Abstract]   [Full Text] [Related]  

  • 34. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient and health-care worker experiences of an HIV viral load intervention using SMS: A qualitative study.
    Venables E; Ndlovu Z; Munyaradzi D; Martínez-Pérez G; Mbofana E; Nyika P; Chidawanyika H; Garone DB; Bygrave H
    PLoS One; 2019; 14(4):e0215236. PubMed ID: 30973925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
    Blanco JL; Gonzalez-Cordón A; Llibre JM; Calvo M; Gutierrez F; Podzamczer D; Laguno M; Fumero E; Murillas J; Mallolas J; Martinez-Rebollar M; Lonca M; Perez I; Gatell JM; Martinez E
    Antivir Ther; 2015; 20(5):487-92. PubMed ID: 24964358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study.
    Chadambuka A; Katirayi L; Muchedzi A; Tumbare E; Musarandega R; Mahomva AI; Woelk G
    BMC Public Health; 2017 Jul; 18(1):57. PubMed ID: 28743251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients.
    Yagura H; Watanabe D; Ashida M; Kushida H; Hirota K; Ikuma M; Ogawa Y; Yajima K; Kasai D; Nishida Y; Uehira T; Yoshino M; Shirasaka T
    J Infect Chemother; 2015 Oct; 21(10):713-7. PubMed ID: 26233886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.